Teva Pharmaceuticals has received FDA approval to manufacture and market Etodolac ER 500 mg. and 600 mg. tablets.
Etodolac ER is the generic version of Wyeth-Ayerst's NSAID Lodine XL. Combined 1999 U.S. brand sales of these two strengths were approximately $40 million.
As the first to file a Paragraph TV certification with respect to these two strengths, Teva will receive 180 days of market exclusivity.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group
Contact
Home
A
E-Base